| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/04/2009 | US7569547 Inhibiting furin with polybasic peptides |
| 08/04/2009 | US7569546 Apolipoprotein A1 mimetics and uses thereof |
| 08/04/2009 | US7569545 Methods of increasing neurotrophic factor expression |
| 08/04/2009 | US7569544 drug biological conjugates used in the diagnosis, prophylaxis, or treatment of nervous system disorders or lysosomal storage diseases; drug delivery; blood brain barriers |
| 08/04/2009 | US7569543 An extracellular matrix (ECM)-binding fragment of Angiopoietin-1 protein or a non-ECM binding fragment of Ang-1 protein that contains a modification in an ECM-binding domain of Ang-1, or a proteolytic resistant fragment of Ang-1 protein that contains a modification in a proteolytic domain of Ang-1 |
| 08/04/2009 | US7569542 can be produced recombinantly using bacterial, yeast, or eukaryotic cell expression system, without having to deal with problems associated with chemical or physical linkages |
| 08/04/2009 | US7569541 Malaria vaccine; cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link between 4-aminoproline and glutamine, and having a central (Asn-Pro-Asn-Ala) |
| 08/04/2009 | US7569540 method for maximal parenteral nutrition substantially without acute or chronic hyperglycemia; includes a source of nutrients (carbohydrates) and an insulinotropic peptide (Glucagon-like-peptides, exendin) |
| 08/04/2009 | US7569539 Oral administration of calcitonin |
| 08/04/2009 | US7569538 Vaccines against cancer of the upper respiratory tract or anogenital carcinomas, such as cervical cancer, using fragments of the cyclin-dependent kinase inhibitor P16 protein |
| 08/04/2009 | US7569537 Peptide antagonists for inhibiting heat shock protein (Hsp 16.3) of Mycobacterium tuberculosis |
| 08/04/2009 | US7569387 Specifically binds an MK61 polypeptide produced by immunizing an animal |
| 08/04/2009 | US7569383 Chimeric flavivirus vectors |
| 08/04/2009 | US7569362 Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing |
| 08/04/2009 | US7569361 Thrombopoietin protein variants |
| 08/04/2009 | US7569352 Method for identifying modulators of the dioxin/aryl hydrocarbon receptor (AHR) |
| 08/04/2009 | US7569229 Monocyte locomotion inhibitory factor |
| 08/04/2009 | US7569227 Monomeric protein of the TGF-β family |
| 08/04/2009 | US7569223 Isolated polypeptide is amino acid sequence; lytic enzyme comprises a first isolated amino acid sequence homolog; In vitro Killing Assay; In vivo Nasal Infection Assay |
| 08/04/2009 | US7569218 Compositions for and methods of using herpes simplex virus glycoprotein D to suppress immune responses |
| 08/04/2009 | US7569216 Anti-virus therapy for respiratory diseases |
| 08/04/2009 | US7569215 Mutant interleukin-2 (IL-2) polypeptides |
| 08/04/2009 | CA2433785C Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 08/04/2009 | CA2323090C In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases |
| 08/04/2009 | CA2320959C Cytokine inducers comprising m161ag |
| 08/04/2009 | CA2247009C Cryptic peptides and method for their identification |
| 08/04/2009 | CA2194673C A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
| 07/30/2009 | WO2009094636A2 Ixodes scapularis salivary proteins and methods of use for modulation of the alternative complement pathway |
| 07/30/2009 | WO2009094438A1 Heteroaryl-containing tripeptide hcv serine protease inhibitors |
| 07/30/2009 | WO2009094202A1 Method of treating cancer, neoplastic disorders, and symptoms thereof with compounds |
| 07/30/2009 | WO2009094137A2 Urotensin-ii agonists |
| 07/30/2009 | WO2009093970A1 Method of improving wound healing |
| 07/30/2009 | WO2009093880A2 Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor |
| 07/30/2009 | WO2009093864A2 Composition for preventing or treating brain diseases |
| 07/30/2009 | WO2009093713A1 Peg-modified hydroxyapatite, pharmaceutical preparation containing the same as base material, and method for production of the same |
| 07/30/2009 | WO2009093671A1 Antidepressant/antianxiety agent |
| 07/30/2009 | WO2009093447A1 Anti-tumor agent for gastrointestinal cancer |
| 07/30/2009 | WO2009093246A2 Clusterin derived peptide |
| 07/30/2009 | WO2009093189A2 Peptides, compositions, and uses thereof |
| 07/30/2009 | WO2009093119A2 Use of serine protease inhibitors in the treatment of skin diseases |
| 07/30/2009 | WO2009092891A2 Modification of intrinsically disordered sequences for preparing vaccines |
| 07/30/2009 | WO2009092806A2 Selective exosite inhibition of papp-a activity against igfbp-4 |
| 07/30/2009 | WO2009092790A1 Listeria monocytogenes cytotoxin listeriolysin s |
| 07/30/2009 | WO2009092758A1 New blood coagulation factor inhibitors |
| 07/30/2009 | WO2009092612A1 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as vehicles for the specific delivery of compounds to the liver |
| 07/30/2009 | WO2009092611A1 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| 07/30/2009 | WO2009092396A1 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| 07/30/2009 | WO2009092323A1 Uses of pdcd5 polypeptide for tumor chemotherapy and organ protection |
| 07/30/2009 | WO2009075882A3 Impaired wound healing compositions and treatments |
| 07/30/2009 | WO2009075881A3 Impaired wound healing compositions and treatments |
| 07/30/2009 | WO2009053725A3 Peptides and uses thereof |
| 07/30/2009 | WO2009052411A3 Methods for treatment of thiol-containing compound deficient conditions |
| 07/30/2009 | WO2009047361A3 Injectable fibrin compositions for tissue augmentation comprising strontium salt |
| 07/30/2009 | WO2009043464A3 Astressin and beta- endorphin for use as therapeutic agents |
| 07/30/2009 | WO2009043451A3 Use of chorionic gonadotropin-beta (109-145) as a therapeutic agent |
| 07/30/2009 | WO2009043450A3 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents |
| 07/30/2009 | WO2009043449A3 Use of a peptide as a therapeutic agent |
| 07/30/2009 | WO2009043447A3 Use of a peptide as a therapeutic agent |
| 07/30/2009 | WO2009040085A3 Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) |
| 07/30/2009 | WO2009040004A3 Use of a peptide as a therapeutic agent |
| 07/30/2009 | WO2009033813A3 Use of a peptide as a therapeutic agent |
| 07/30/2009 | WO2009033774A3 Use of a laminin nonapeptide as a therapeutic agent |
| 07/30/2009 | WO2009033769A3 Use of cortistatin 14 and others as a therapeutic agent |
| 07/30/2009 | WO2009033722A8 Use of a octreotide as a therapeutic agent |
| 07/30/2009 | WO2009025864A8 Methods of treating and protecting against human immunodeficiency virus |
| 07/30/2009 | WO2009025759A8 Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof |
| 07/30/2009 | WO2008157302A3 Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |
| 07/30/2009 | WO2008154638A8 Antagonists of the receptor for advanced glycation end-products (rage) |
| 07/30/2009 | WO2008145013A8 Fusion protein comprising targeting peptide of cd13 and lidamycin |
| 07/30/2009 | WO2008138348A8 Preparation of complexed lactalbumin |
| 07/30/2009 | WO2008127975A3 Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis |
| 07/30/2009 | WO2008101406A8 Modified mutant collagenase and it's use in fat melting and in scar reduction |
| 07/30/2009 | WO2008100449A4 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| 07/30/2009 | WO2008085543A8 Multimeric elp fusion constructs |
| 07/30/2009 | WO2008073957A8 Compounds and methods for modulating the silencing of a polynucleotide of interest |
| 07/30/2009 | WO2008067223A8 Il-17a/f heterodimeric polypeptides and therapeutic uses thereof |
| 07/30/2009 | WO2008055059A8 Bi-functional peptides for multiple sclerosis treatment and diagnosis |
| 07/30/2009 | WO2008051496A8 Use of il-1 antagonists to treat gout and pseudogout |
| 07/30/2009 | WO2008033820A8 Modifications of cupredoxin derived peptides and methods of use thereof |
| 07/30/2009 | WO2008022153A8 Inhibitors of pde4 and methods of use |
| 07/30/2009 | WO2008017734A8 Polymyxin derivatives and uses thereof |
| 07/30/2009 | WO2007147945A8 Modified beta-lactamase and method for its preparation |
| 07/30/2009 | WO2007137591A8 Hiv vaccine |
| 07/30/2009 | WO2007136635A8 Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators |
| 07/30/2009 | WO2007118431A8 Use of trap protein as active ingredient for manufacturing a medicament for the treatment of staphylococcus aureus infection |
| 07/30/2009 | WO2007112682A8 Recombinant human parathyroid hormone-related proteins and uses thereof |
| 07/30/2009 | WO2007110772A8 Immunomodulating oligopeptides |
| 07/30/2009 | WO2007104263A8 An enhancin of hepatitis b virus vaccine and its gene |
| 07/30/2009 | WO2007096745A8 Methods for the treatment of macular degeneration and related eye conditions |
| 07/30/2009 | US20090193531 Methods and compositions for RNA Interference |
| 07/30/2009 | US20090192474 Delivery system |
| 07/30/2009 | US20090192295 Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans |
| 07/30/2009 | US20090192292 Murine zcytor17 ligand polypeptides and polynucleotides |
| 07/30/2009 | US20090192291 Production of homotrimeric fusion proteins |
| 07/30/2009 | US20090192189 Treatment of cancers expressing p95 erbb2 |
| 07/30/2009 | US20090192183 Oxymorphone Controlled Release Formulations |
| 07/30/2009 | US20090192109 Compositions for diagnosis and therapy of diseases associated with aberrant expression of Kremen and/or Wnt |
| 07/30/2009 | US20090192106 MODULATION OF eIF4E EXPRESSION |
| 07/30/2009 | US20090192105 RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA) |
| 07/30/2009 | US20090192104 RNA INTERFERENCE MEDIATED INHIBITION OF HYPOXIA INDUCIBLE FACTOR 1 (HIF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |